Diametric Capital’s Protalix BioTherapeutics PLX Stock Holding History

Diametric Capital’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-124,195	Closed	-$270K	–	639
2026 Q1	$270K	Sell	124,195 -14,734	-11%	-$36.6K	0.07%	354
2025 Q4	$250K	Sell	138,929 -41,055	-23%	-$83.9K	0.07%	326
2025 Q3	$400K	Buy	179,984 +36,712	+26%	+$59.8K	0.15%	183
2025 Q2	$212K	Buy	+143,272	New	+$293K	0.11%	250

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Diametric Capital's PLX Position: Q2 2026 in Review

Diametric Capital sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 124,195 shares — an estimated $270K sold.

Diametric Capital first reported a position in PLX in Q2 2025 and held it in 4 quarters. The position peaked at $400K in Q3 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Diametric Capital reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
Diametric Capital sold 124,195 Protalix BioTherapeutics shares in Q2 2026, an estimated $270K.
Diametric Capital first reported a position in Protalix BioTherapeutics in Q2 2025 and held it in 4 quarters.
Diametric Capital's Protalix BioTherapeutics position peaked at $400K in Q3 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.